CSL Vifor proposes a marketing campaign to settle European Commission investigation
CSL Vifor is looking to close out a European anti-competitive investigation with a proposed marketing campaign.
The European Commission began investigating Vifor Pharma, now CSL Vifor, in June 2022 over allegations it illegally disparaged its IV iron infusion competitor, Pharmacosmos’ Monofer. The EC alleged Vifor’s actions were aimed at stifling competition for its own high-dose iron IV brand Ferinject, which is marketed as Injectafer in the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.